Vuong Thi Ngoc Lan, Ho M T, Ha T Q, Jensen M Brehm, Andersen C Yding, Humaidan P
Department of Obstetrics and Gynaecology, University of Medicine and Pharmacy HCMC, 217 Hong Bang Street, District 5, Ho Chi Minh City, Vietnam.
IVFMD, My Duc Hospital, 4 Nui Thanh Street, Tan Binh District, Ho Chi Minh City, Vietnam.
J Assist Reprod Genet. 2017 Apr;34(4):471-478. doi: 10.1007/s10815-017-0891-9. Epub 2017 Feb 14.
A recent dose-finding study showed no significant differences in number of mature oocytes, embryos and top-quality embryos when triptorelin doses of 0.2, 0.3 or 0.4 mg were used to trigger final oocyte maturation in oocyte donors co-treated with a gonadotropin-releasing hormone (GnRH) antagonist. This analysis investigated whether triptorelin dosing for triggering final oocyte maturation in oocyte donors induced differences in follicular fluid (FF) hormone levels and granulosa cell gene expression.
This single-centre, randomised, parallel, investigator-blinded trial was conducted in oocyte donors undergoing a single stimulation cycle at IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam, from August 2014 to March 2015. A total of 165 women aged 18-35 years with body mass index <28 kg/m, anti-Müllerian hormone >1.25 ng/mL, and antral follicle count ≥6 were randomised to three different triptorelin doses for trigger. The main outcome was concentration of steroid hormones in FF collected from the first punctured follicle on each side. Moreover, luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD) and inhibin-Ba (INHB-A) gene expression in cumulus and mural granulosa cells were investigated in a subset of women from each group.
Progesterone and oestradiol levels in FF did not differ significantly by trigger doses; findings were similar for 3βHSD, LHR and INHB-A gene expression in both cumulus and mural granulosa cells.
In women co-treated with a GnRH antagonist, no significant differences in FF steroid levels and granulosa cell gene expression were seen when different triptorelin doses were used to trigger final oocyte maturation.
最近一项剂量探索性研究表明,在与促性腺激素释放激素(GnRH)拮抗剂联合治疗的卵母细胞供体中,使用0.2、0.3或0.4毫克曲普瑞林剂量触发最终卵母细胞成熟时,成熟卵母细胞、胚胎和优质胚胎的数量没有显著差异。本分析调查了用于触发卵母细胞供体最终卵母细胞成熟的曲普瑞林剂量是否会引起卵泡液(FF)激素水平和颗粒细胞基因表达的差异。
本单中心、随机、平行、研究者盲法试验于2014年8月至2015年3月在越南胡志明市美福医院体外受精与胚胎移植科接受单周期刺激的卵母细胞供体中进行。共有165名年龄在18 - 35岁、体重指数<28kg/m²、抗苗勒管激素>1.25ng/mL且窦卵泡计数≥6的女性被随机分配到三种不同的曲普瑞林触发剂量组。主要结局是从每侧第一个穿刺卵泡收集的FF中甾体激素的浓度。此外,在每组的一部分女性中研究了卵丘和壁层颗粒细胞中促黄体生成素受体(LHR)、3β - 羟基甾体脱氢酶(3ßHSD)和抑制素 - Ba(INHB - A)基因的表达。
FF中的孕酮和雌二醇水平在触发剂量之间没有显著差异;卵丘和壁层颗粒细胞中3βHSD、LHR和INHB - A基因表达的结果相似。
在与GnRH拮抗剂联合治疗的女性中,使用不同曲普瑞林剂量触发最终卵母细胞成熟时,FF甾体水平和颗粒细胞基因表达没有显著差异。